Evidence map›Paper›PMID 26901236›Full record

ArticleBioengineered2016

MicroRNA, a new target for engineering new crop cultivars.

Baohong Zhang, Qinglian Wang

Open access · goldAbstract read
In one paragraph

Article in Bioengineered, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
8.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 35 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Contribution of Omics and Systems Biology to Plant Biotechnology.Advances in experimental medicine and biology · 2021
    Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 2 countries.

Baohong Zhanga Henan Collaborative Innovation Center of Modern Biological Breeding, School of Life Science and Technology, Henan Institute of Science and Technology , Xinxiang , China.
Qinglian Wanga Henan Collaborative Innovation Center of Modern Biological Breeding, School of Life Science and Technology, Henan Institute of Science and Technology , Xinxiang , China.
Henan Institute of Science and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Global sustainable development depends on, at least partially, the sustainable development of crop reproduction that provides food, cloth and bioenergy as well certain drugs. During thousands of years of human history, many crops have been domesticated for feeding the world. Perfectly, in the past 2 decades, scientists have innovated biotechnological tools for improving crop yield and quality. For sustainable development, more targets and tools are needed to develop. Among these, microRNA (miRNA) is becoming an emerging target for engineering new crop cultivars with high yield and quality as well tolerance to environmental abiotic and biotic stresses. miRNAs are an extensive class of small regulatory RNAs, which play essential roles in all plant biological and metabolic processes, not only in plant development and growth but also in compound biosynthesis and response to various environmental stress. miRNA-based biotechnology is becoming a new strategy for crop improvement, which will play important role in future agricultural sustainable development.

Indexed as

Gene Expression Regulation, PlantPlants, Genetically ModifiedArabidopsisCrops, AgriculturalDisease ResistanceGenetic EngineeringHumansMicroRNAsOryzaPlant DiseasesSolanum lycopersicumZea maysMicroRNAsBiotechnologycrop improvementengineeringmicroRNAplantsustainable agricultural development

Identifiers

PMID26901236
PMCPMC4878270
OpenAlexW2276681649

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.